Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 18 is a processed pseudogene corresponding to the ribosomal protein L21 gene. Pseudogenes resemble functional protein-coding genes in sequence but are considered nonfunctional because they typically contain disabling mutations or lack regulatory elements, resulting in no functional protein product[2][8]. RPL21P18 is one of many processed pseudogenes derived from RPL21, a ribosomal protein that is part of the 60S ribosomal subunit[4][8]. There is no evidence this pseudogene encodes an active protein or serves as a therapeutic target. RPL21P18 is a non-functional processed pseudogene of the ribosomal protein L21 gene and is not considered a therapeutic target; its relevance is primarily genomic rather than functional or clinical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 18 (RPL21P18).